Cargando…
Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors
BACKGROUND: To conduct a systematic review and meta-analysis to assess the overall incidence and risk of interstitial lung disease (ILD) and QTc prolongation associated with anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (-TKIs) in non-small-cell lung cancer (NSCLC) patients. RESULTS: A...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593649/ https://www.ncbi.nlm.nih.gov/pubmed/28915678 http://dx.doi.org/10.18632/oncotarget.18283 |
_version_ | 1783263082032660480 |
---|---|
author | Lin, Liping Zhao, Juanjuan Kong, Ning He, Yan Hu, Jiazhu Huang, Fuxi Han, Jianjun Cao, Xiaolong |
author_facet | Lin, Liping Zhao, Juanjuan Kong, Ning He, Yan Hu, Jiazhu Huang, Fuxi Han, Jianjun Cao, Xiaolong |
author_sort | Lin, Liping |
collection | PubMed |
description | BACKGROUND: To conduct a systematic review and meta-analysis to assess the overall incidence and risk of interstitial lung disease (ILD) and QTc prolongation associated with anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (-TKIs) in non-small-cell lung cancer (NSCLC) patients. RESULTS: A total of 1,770 patients from 8 clinical trials were included. The incidences of high-grade ILD and QTc prolongation was 2.5% (95% CI 1.7-3.6%), and 2.8% (95% CI 1.8-4.3%), respectively. Meta-analysis demonstrated that the use of ALK-TKIs in NSCLC patients significantly increased the risk of developing high-grade ILD (Peto OR, 3.27, 95%CI: 1.18–9.08, p = 0.023) and QTc prolongation (Peto OR 7.51, 95% CI, 2.16–26.15; p = 0.002) in comparison with chemotherapy alone. MATERIALS AND METHODS: A systematic literature search was performed to identify related citations up to January 31, 2017. Data were extracted, and summary incidence rates, Peto odds ratios (Peto ORs), and 95% confidence intervals (CIs) were calculated. CONCLUSIONS: The use of ALK-TKIs significantly increases the risk of developing high-grade ILD and QTc prolongation in lung cancer patients. Clinicians should pay attention to the risks of severe ILD and QTc prolongation with the administration of these drugs. |
format | Online Article Text |
id | pubmed-5593649 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-55936492017-09-14 Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors Lin, Liping Zhao, Juanjuan Kong, Ning He, Yan Hu, Jiazhu Huang, Fuxi Han, Jianjun Cao, Xiaolong Oncotarget Meta-Analysis BACKGROUND: To conduct a systematic review and meta-analysis to assess the overall incidence and risk of interstitial lung disease (ILD) and QTc prolongation associated with anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (-TKIs) in non-small-cell lung cancer (NSCLC) patients. RESULTS: A total of 1,770 patients from 8 clinical trials were included. The incidences of high-grade ILD and QTc prolongation was 2.5% (95% CI 1.7-3.6%), and 2.8% (95% CI 1.8-4.3%), respectively. Meta-analysis demonstrated that the use of ALK-TKIs in NSCLC patients significantly increased the risk of developing high-grade ILD (Peto OR, 3.27, 95%CI: 1.18–9.08, p = 0.023) and QTc prolongation (Peto OR 7.51, 95% CI, 2.16–26.15; p = 0.002) in comparison with chemotherapy alone. MATERIALS AND METHODS: A systematic literature search was performed to identify related citations up to January 31, 2017. Data were extracted, and summary incidence rates, Peto odds ratios (Peto ORs), and 95% confidence intervals (CIs) were calculated. CONCLUSIONS: The use of ALK-TKIs significantly increases the risk of developing high-grade ILD and QTc prolongation in lung cancer patients. Clinicians should pay attention to the risks of severe ILD and QTc prolongation with the administration of these drugs. Impact Journals LLC 2017-05-29 /pmc/articles/PMC5593649/ /pubmed/28915678 http://dx.doi.org/10.18632/oncotarget.18283 Text en Copyright: © 2017 Lin et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Meta-Analysis Lin, Liping Zhao, Juanjuan Kong, Ning He, Yan Hu, Jiazhu Huang, Fuxi Han, Jianjun Cao, Xiaolong Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors |
title | Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors |
title_full | Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors |
title_fullStr | Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors |
title_full_unstemmed | Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors |
title_short | Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors |
title_sort | meta-analysis of the incidence and risks of interstitial lung disease and qtc prolongation in non-small-cell lung cancer patients treated with alk inhibitors |
topic | Meta-Analysis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593649/ https://www.ncbi.nlm.nih.gov/pubmed/28915678 http://dx.doi.org/10.18632/oncotarget.18283 |
work_keys_str_mv | AT linliping metaanalysisoftheincidenceandrisksofinterstitiallungdiseaseandqtcprolongationinnonsmallcelllungcancerpatientstreatedwithalkinhibitors AT zhaojuanjuan metaanalysisoftheincidenceandrisksofinterstitiallungdiseaseandqtcprolongationinnonsmallcelllungcancerpatientstreatedwithalkinhibitors AT kongning metaanalysisoftheincidenceandrisksofinterstitiallungdiseaseandqtcprolongationinnonsmallcelllungcancerpatientstreatedwithalkinhibitors AT heyan metaanalysisoftheincidenceandrisksofinterstitiallungdiseaseandqtcprolongationinnonsmallcelllungcancerpatientstreatedwithalkinhibitors AT hujiazhu metaanalysisoftheincidenceandrisksofinterstitiallungdiseaseandqtcprolongationinnonsmallcelllungcancerpatientstreatedwithalkinhibitors AT huangfuxi metaanalysisoftheincidenceandrisksofinterstitiallungdiseaseandqtcprolongationinnonsmallcelllungcancerpatientstreatedwithalkinhibitors AT hanjianjun metaanalysisoftheincidenceandrisksofinterstitiallungdiseaseandqtcprolongationinnonsmallcelllungcancerpatientstreatedwithalkinhibitors AT caoxiaolong metaanalysisoftheincidenceandrisksofinterstitiallungdiseaseandqtcprolongationinnonsmallcelllungcancerpatientstreatedwithalkinhibitors |